Follow the people · Insider
Melanie Gloria
Melanie Gloria files insider transactions with the SEC as a chief operating officer of Immunovant (IMVT). We hold 6 disclosed purchases and sales filed since 4 May 2023, 3 of them in the last 90 days.
- Files forIMVT
- Disclosed buys and sells6 in all, 3 in the last 90 days
- Last disclosure21 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 18 November 2024 — 20 August 2026Chief Operating Officer · Immunovant (IMVT)23 Form 4 lines · source: SEC Form 4
- Filed 4 May 2023 — 23 May 2024Chief Operating Officer · Acelyrin (SLRN)11 Form 4 lines · source: SEC Form 4
Everything they disclosed
34 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 3,056 shares of ImmunovantSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- ▼ sold on the open market 1,930 shares of ImmunovantSEC Form 410 July 2026Common Stock · traded 8 July 2026 · filed 10 July 2026
- ▼ sold on the open market 106 shares of ImmunovantSEC Form 410 July 2026Common Stock · traded 8 July 2026 · filed 10 July 2026
- ▼ sold on the open market 14,748 shares of ImmunovantSEC Form 426 June 2026Common Stock · traded 26 June 2026 · filed 26 June 2026
- ▼ sold on the open market 2,966 shares of ImmunovantSEC Form 426 June 2026Common Stock · traded 26 June 2026 · filed 26 June 2026
- ▼ sold on the open market 249 shares of ImmunovantSEC Form 422 May 2026Common Stock · traded 20 May 2026 · filed 22 May 2026
- ▼ sold on the open market 1,168 shares of ImmunovantSEC Form 422 May 2026Common Stock · traded 20 May 2026 · filed 22 May 2026
- ▼ sold on the open market 1,698 shares of ImmunovantSEC Form 422 May 2026Common Stock · traded 20 May 2026 · filed 22 May 2026
- ▼ sold on the open market 8,722 shares of ImmunovantSEC Form 410 April 2026Common Stock · traded 8 April 2026 · filed 10 April 2026
- was granted 83,671 shares of ImmunovantSEC Form 49 April 2026Common Stock · traded 7 April 2026 · filed 9 April 2026
- was granted 121,063 shares of Immunovant (a derivative holding)SEC Form 49 April 2026Stock Option (right to buy) · traded 7 April 2026 · filed 9 April 2026
- ▼ sold on the open market 1,437 shares of ImmunovantSEC Form 427 February 2026Common Stock · traded 25 February 2026 · filed 27 February 2026
- ▼ sold on the open market 859 shares of ImmunovantSEC Form 427 February 2026Common Stock · traded 25 February 2026 · filed 27 February 2026
- ▼ sold on the open market 942 shares of ImmunovantSEC Form 427 February 2026Common Stock · traded 25 February 2026 · filed 27 February 2026
- ▼ sold on the open market 1,437 shares of ImmunovantSEC Form 427 February 2026Common Stock · traded 25 February 2026 · filed 27 February 2026
- ▼ sold on the open market 859 shares of ImmunovantSEC Form 427 February 2026Common Stock · traded 25 February 2026 · filed 27 February 2026
- ▼ sold on the open market 942 shares of ImmunovantSEC Form 427 February 2026Common Stock · traded 25 February 2026 · filed 27 February 2026
- ▼ sold on the open market 10,251 shares of ImmunovantSEC Form 421 November 2025Common Stock · traded 20 November 2025 · filed 21 November 2025
- ▼ sold on the open market 2,375 shares of ImmunovantSEC Form 421 November 2025Common Stock · traded 20 November 2025 · filed 21 November 2025
- was granted 107,297 shares of Immunovant (a derivative holding)SEC Form 43 April 2025Stock Option (right to buy) · traded 1 April 2025 · filed 3 April 2025
- was granted 76,181 shares of ImmunovantSEC Form 43 April 2025Common Stock · traded 1 April 2025 · filed 3 April 2025
- was granted 137,446 shares of Immunovant (a derivative holding)SEC Form 420 November 2024Stock Option (right to buy) · traded 18 November 2024 · filed 20 November 2024
- was granted 109,956 shares of ImmunovantSEC Form 420 November 2024Common Stock · traded 18 November 2024 · filed 20 November 2024
- was granted 184,042 shares of Acelyrin (a derivative holding)SEC Form 424 May 2024Employee Stock Option (right to buy) · traded 23 May 2024 · filed 24 May 2024
- had shares withheld for tax on 10,298 shares of AcelyrinSEC Form 417 May 2024Common Stock · traded 15 May 2024 · filed 17 May 2024
- was granted 494,297 shares of Acelyrin (a derivative holding)SEC Form 411 January 2024Employee Stock Option (right to buy) · traded 9 January 2024 · filed 11 January 2024
- was granted 140,584 shares of AcelyrinSEC Form 418 August 2023Common Stock · traded 16 August 2023 · filed 18 August 2023
- acquired or disposed of, other 330,181 shares of Acelyrin (a derivative holding)SEC Form 411 May 2023Employee Stock Option (right to buy) · traded 9 May 2023 · filed 11 May 2023
- acquired or disposed of, other 330,181 shares of Acelyrin (a derivative holding)SEC Form 411 May 2023Employee Stock Option (right to buy) · traded 9 May 2023 · filed 11 May 2023
- acquired or disposed of, other 187,988 shares of Acelyrin (a derivative holding)SEC Form 411 May 2023Employee Stock Option (right to buy) · traded 9 May 2023 · filed 11 May 2023
- acquired or disposed of, other 187,988 shares of Acelyrin (a derivative holding)SEC Form 411 May 2023Employee Stock Option (right to buy) · traded 9 May 2023 · filed 11 May 2023
- acquired or disposed of, other 232,436 shares of Acelyrin (a derivative holding)SEC Form 411 May 2023Employee Stock Option (right to buy) · traded 9 May 2023 · filed 11 May 2023
- acquired or disposed of, other 232,436 shares of Acelyrin (a derivative holding)SEC Form 411 May 2023Employee Stock Option (right to buy) · traded 9 May 2023 · filed 11 May 2023
- was granted 232,436 shares of Acelyrin (a derivative holding)SEC Form 44 May 2023Employee Stock Option (right to buy) · traded 4 May 2023 · filed 4 May 2023
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.